<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911129-0053</DOCNO><DOCID>911129-0053.</DOCID><HL>   Business Brief -- Bristol-Myers Squibb Co.:   Schering to Get U.S. Rights   To Irregular-Heartbeat Drug</HL><DATE>11/29/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   BMY G.SCH</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)</IN><NS>LICENSING AGREEMENTS (LIC)</NS><RE>EUROPE (EU)GERMANY (GE)NORTH AMERICA (NME)NEW YORK (NY)UNITED STATES (US)WESTERN EUROPE (WEU)</RE><LP>   Bristol-Myers Squibb Co. said it reached an agreementgiving Schering AB of Germany the U.S. rights to Betapace, atreatment for irregular heartbeat awaiting regulatoryapproval.   Bristol-Myers said it will receive a licensing fee plusroyalties on U.S. Betapace sales. It also will receiveworld-wide rights under Schering's existing patents andpatent applications relating to ProHance, a Bristol-Myerscontrast agent used in magnetic resonance imaging. ABristol-Myers spokesman noted that Schering holds broadpatents in the magnetic resonance area and said that whileBristol-Myers believes its ProHance patent is valid, itwanted to minimize the risk of litigation.</LP><TEXT>   Once ProHance is approved by the Food and DrugAdministration, ProHance will be marketed by SquibbDiagnostics, a division of Bristol-Myers.</TEXT></DOC>